Biogen Buys Apellis: Rare Disease Biotech

Biogen is making one of the bigger biotech moves on the tape, agreeing to buy Apellis for about $5.6 billion in cash. The key trading angle is that this can lift sentiment around commercial-stage biotech and rare disease names that could be seen as future takeover candidates, while also putting pressure on Biogen itself as traders weigh the size, financing, and execution risk of the deal.

Winners

Rare disease biotech takeover candidates

A large-premium biotech deal can make investors re-rate other U.S.-listed rare disease companies with approved products, specialist commercial infrastructure, or attractive pipelines. The market may start looking for the next possible acquisition target in the same broad space.

Names: $ALNY (Alnylam Pharmaceuticals), $RARE (Ultra ...